Surfaktantbehandling af nyfødte med respiratorisk distress-syndrom primaert behandlet med nasalt kontinuerligt positivt luftvejstryk. En pilotundersøgelse

H Verder, L Agertoft, P Albertsen, T Curstedt, F Ebbesen, G Greisen, N Hobolth, V Holm

Abstract

In this pilot study, Curosurf (200 mg/kg) was administrated to 34 patients with the respiratory distress syndrome in nasal-CPAP therapy with FiO2 requirements greater than 0.60 and/or TcPCO2 greater than 8 kPa. The surfactant was instilled during a short period of intubation or in a few cases via an intratracheal catheter (Ch. 6). The age of the patients on surfactant treatment ranged from two to 72 hours. Eighteen patients could be maintained on nasal-CPAP after treatment with Curosurf and only a few complications were seen in these infants. The other 16 patients subsequently required artificial ventilation and had a higher incidence of pulmonary and extrapulmonary complications. On the basis of these observations, we plan a randomized trial to investigate whether, administration of surfactant reduces the need for ventilator treatment and improves the odds for uneventful recovery in this category of patients.

Bidragets oversatte titelSurfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind154
Udgave nummer31
Sider (fra-til)2136-9
Antal sider4
ISSN0041-5782
StatusUdgivet - 27 jul. 1992

Emneord

  • Biological Products
  • Denmark
  • Humans
  • Infant, Newborn
  • Phospholipids
  • Pilot Projects
  • Positive-Pressure Respiration
  • Pulmonary Surfactants/administration & dosage
  • Respiratory Distress Syndrome, Newborn/diagnosis

Fingeraftryk

Dyk ned i forskningsemnerne om 'Surfaktantbehandling af nyfødte med respiratorisk distress-syndrom primaert behandlet med nasalt kontinuerligt positivt luftvejstryk. En pilotundersøgelse'. Sammen danner de et unikt fingeraftryk.

Citationsformater